Private healthcare firm, MedLife, surpasses the 500 million euro mark in revenue by the year 2024, making history as the first such company in Romania to achieve this milestone.
MedLife, Romania's largest private healthcare network, has announced its strategic plans for 2025. The focus is on organic growth through innovation, acquisitions, and expansion in wellness, corporate healthcare, and mental health services.
Innovation and Organic Growth
MedLife is set to invest €3 million in genetic testing technology and will launch Romania's first large-scale genetic testing program using whole genome sequencing (WGS) in October 2025. This initiative aims to personalize patient care and expand MedLife's diagnostics capabilities.
Acquisitions
While specific acquisitions by MedLife in 2025 are yet to be detailed, the Romanian private healthcare sector has seen notable private equity activity, indicating a favorable climate for MedLife to leverage acquisitions for growth.
Wellness Expansion
MedLife might align with luxury and wellness market trends by expanding holistic health and wellness services, possibly integrating genetic insights to offer personalized wellness solutions.
Corporate Segment
MedLife is expected to focus on growing its corporate client base, including telemedical services, consistent with CEE healthcare trends. However, no explicit details about corporate healthcare expansion have been provided.
Mental Health
While no direct information about MedLife’s mental health initiatives specifically for 2025 has been disclosed, the surge in telemedicine and online consultation platforms suggests a probable strategic interest by MedLife in expanding mental health services through digital platforms.
Expansion in 2024
In 2024, MedLife made several strategic moves, including the acquisition of Antares Clinic, a significant private healthcare provider in Moldova, and Euromedica Group Baia Mare. The network of mental health clinics, MindCare, also expanded with two new units in Constanta and Craiova.
Additionally, MedLife inaugurated three hospitals in Bucharest, Craiova, and Timisoara, becoming a major provider of hospital services in those locations. The company also acquired SWEAT, the fitness network within the MedLife Group, which resulted in investments of approximately two million euros in two new locations in Bucharest.
Financial Performance
In 2024, MedLife reported a pro-forma net profit of RON 33 million and a pro-forma EBITDA of RON 412 million, up from RON 317 million in the previous year. The company consolidated its leading position in the field of genetic sequencing and medical innovation, and achieved a pro forma consolidated turnover of over RON 2.7 billion (EUR 555 million), up 25% compared to 2023. MedLife became the first Romanian company in the private healthcare sector to exceed half a billion euros in turnover in 2024.
Outlook for 2025
Mihai Marcu, President and CEO of MedLife Group, declared optimism about the company's financial and operational business performance in 2024. He plans to emphasize the wellness component and launch products that combine prevention and a healthy lifestyle in 2025. MedLife aims to continue development projects started in 2024, with a focus on expansion and acquisition opportunities. The company plans to expand its network of hyperclinics, add a new radiotherapy center in the north-east of the country, and open new units dedicated to mental health and fitness in Bucharest and across the country in 2025.
In conclusion, MedLife’s 2025 strategy centers on innovation via genetic testing, potential acquisitions aligned with a dynamic healthcare M&A environment, and likely expansion in wellness and corporate sectors supported by telemedicine trends, with implied but unspecified plans to develop mental health services.
[1] MedLife Press Release, www.medlife.ro [2] Romania Insider, www.romania-insider.com [3] Romania-Insider.com, www.romania-insider.com [4] Luxury Daily, www.luxurydaily.com [5] CEE Healthcare Markets, www.ceehealthcaremarkets.com
- To amplify its diagnostics capabilities, MedLife will invest €3 million in genetic testing technology and launch a large-scale genetic testing program using whole genome sequencing (WGS) in October 2025, aiming to personalize patient care and enrich its science-driven approach.
- During the corporate fiscal year of 2025, MedLife might consider diversifying its business portfolio by delving into personal-finance services, as part of their holistic health and wellness offerings, given the positive growth trends in the finance sector and their strategic plans for a comprehensive health and well-being approach.
- On the path to becoming a pioneer in the health-and-wellness market, MedLife may pursue partnerships with fitness-and-exercise brands to introduce dynamic wellness programs tailored for its client base, leveraging the insights gained from its genetic testing initiatives to offer bespoke fitness solutions.
